Innovative Chemistry Platform Generating Therapeutics for Neurodegenerative Diseases
First-in-class small molecules modulating three complementary upstream mechanisms involved in neurodegeneration
Our Trojan Horse
Ilios is the ancient name of Troy. Our Trojan Horse delivers multi-targeted drugs to the brain to combat neurodegeneration.
Multi-targeted
Small Molecules
Modulating three complementary mechanisms: brain inflammation, oxidative stress, and the aggregation of selected misfolded proteins
Novel Chemistry, Validated Agents
Merging privileged bioactive pharmacophores with glutathione and fatty acids to create proprietary New Chemical Entities (NCEs)
Intelligent Drug Discovery
Utilizing a machine learning trained model and our own library to screen through millions of permutations
Modular
Platform
Facilitating rational design of treatments for ALS, Frontotemporal Dementia, Parkinson's, and Alzheimer's Disease
Novel approach to neurodegeneration
Target multiple complementary mechanisms with a single drug
First in class small molecules optimized to target three upstream pathways that play a key role in the neurodegenerative cascade: misfolded protein disaggregation, brain inflammation and oxidative stress
Synergistic activity in rationally designed NCEs merging validated naturally occurring ligands
Our modular chemistry platform merges bioactive pharmacophores with Glutathione and Fatty Acids to create New Chemical Entities (NCEs). These are designed to synergistically modulate multiple mechanisms involved in neurodegeneration
Delivering superior molecules using an innovative med-chem approach
-
Abundance of pre-clinical and clinical data demonstrate the biological activity of natural ligands
-
Benefits of nature-derived bioactive compounds
✓ Superior drug-like properties: stability and oral bioavailability
✓ Increased lipophilicity for enhanced cell penetration
✓ Reduced toxicity and improved safety profile
Our first indication is ALS-FTD
